153196-51-1

Usage

Uses

Used in Pharmaceutical Research and Development:
BHTM is used as a chemical compound in the research and development of potential drugs targeting specific receptors in the central nervous system. Its unique chemical structure allows it to interact with these receptors, potentially leading to the development of new treatments for neurological and psychiatric disorders.
Used in the Treatment of Neurological Disorders:
BHTM is used as a potential therapeutic agent for neurological disorders. Its interaction with specific receptors in the central nervous system may provide a new avenue for treating conditions such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis.
Used in the Treatment of Psychiatric Disorders:
BHTM is also used as a potential therapeutic agent for psychiatric disorders. Its potential to modulate central nervous system receptors could lead to the development of new treatments for conditions such as depression, anxiety, and schizophrenia.
Note: The specific applications and reasons for using BHTM in the treatment of neurological and psychiatric disorders are not provided in the materials. The uses listed above are based on the general information about BHTM's potential applications in the research and development of drugs targeting the central nervous system. Further research is needed to confirm these applications and understand the specific reasons for their use.

Upstream product

• 153196-48-6 N-<(1-benzyl-1,2,3,6-tetrahydro-4-pyridyl)methyl>acetamide 
• 100-39-0 benzyl bromide 
• 23974-15-4 N-(4-Pyridinylmethyl)acetamide 
• 3731-53-1 4-(aminomethyl)pyridine 
• 111080-65-0 (pyridin-4-ylmethyl)carbamic acid tert-butyl ester 
• 1443118-11-3 tert-butyl ((1-benzyl-1,2,3,6-tetrahydropyridin-4-yl)methyl)carbamate 

Downstream Products

• 131839-63-9 N-(1-benzyl-1,2,3,6-tetrahydropyridin-4-yl)-methyl-2-cyclohexyl-2-hydroxy-2-phenylacetamide 
• 1027058-72-5 N-(1-Benzyl-1,2,3,6-tetrahydro-pyridin-4-ylmethyl)-2-chloro-2-cyclohexyl-2-phenyl-acetamide 

Relevant academic research and scientific papers

CANCER TREATMENTS TARGETING CANCER STEM CELLS

Disclosed are compounds, methods, compositions, and kits that allow for treating cancer by, e.g., targeting cancer stem cells. In some embodiments, the cancer is colorectal cancer, gastric cancer, gastrointestinal stromal tumor, ovarian cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, testicular cancer, or lymphoma. In some embodiments, the cancer is liver cancer, endometrial cancer, leukemia, or multiple myeloma. The compounds utilized in the disclosure are of Formula (0), (O'), and (I):

Agents for the treatment of overactive detrusor. VI. Synthesis and pharmacological properties of acetamide derivatives bearing cyclic amines in N-substituents

With the aim of improving of the efficacy and decreasing the side effects of oxybutynin (1), N-[(tetrahydro-3- or 4-pyridyl)methyl]-, N-(4-piperidyl)- , and N-(3- or 4-piperidylalkyl)-2-hydroxyacetamides (3a-n, 4a-g) and the related carboxamides (3o-r, 4h-k, 13', 17) were synthesized and evaluated for inhibitory activity against urinary bladder rhythmic contraction in rats and for mydriatic activity in rats. Some of these compounds were superior to oxybutynin in both inhibitory activity against bladder contraction and selectivity between inhibitory activity against bladder contraction and mydriatic activity. Among them, N-[(1,2,3,6-tetrahydro-4-pyridyl)methyl]- and N-[(1,2,3,6-tetrahydro-1-methyl-4-pyridyl)methyl]-2-hydroxy-2,2- diphenylacetamide (3e, 3f) exhibited the most potent inhibitory activity against bladder contraction (ED30 = 0.005 and 0.003 mg/kg i.v., respectively). Judging from the effect of 3e on detrusor contraction in vitro in guinea-pigs, it appeared that the inhibitory activity of 3e against bladder contraction in vivo was related mainly to its inhibitory activity against detrusor contraction in vitro induced with carbacol (antimuscarine- like activity). The selectivity (20-fold) of 3e between inhibitory activity against bladder contraction and mydriatic activity was greatly superior to that (0.48-fold) of oxybutynin. Compound 3e was synthesized by debenzylation (method E or F) of the corresponding N-[[1-(4-methoxybenzyl)-tetrahydro-4- pyridyl]methyl] derivative (3k), which was prepared by acylation (method B) of the corresponding (tetrahydro-4-pyridyl)methylamine (7k) or by reduction (method D) of the corresponding pyridinium chloride (14k) with NaBH4.